Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Guanethidine
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Guanethidine

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed9 referencesApproximately 4 min read

An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 3 complete abstracts (793 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; Octadine; Oktadin; Isobarin; Guanethidine Sulfate (1:2); Guanethidine Monosulfate; Monosulfate, Guanethidine; Guanethidine Sulfate (1:1).

Where it fits in the MeSH classification

Broader topics
Guanidines

Research landscape

PubMed indexes 3,787 records tagged with the MeSH heading “Guanethidine” (counts retrieved 2026-10-31). 11 of them (0.3%) were published from 2020 onward, and the busiest period so far is through 1999 with 3,560 records.

Reviews account for 164 records (4.3%) and meta-analyses for 2. Randomized controlled trials number 41 (1.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 3,560 records; 2000-2009: 161 records; 2010-2019: 55 records; 2020 onward: 11 records3,560through 19991612000-2009552010-2019112020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19993,560
2000-2009161
2010-201955
2020 onward11
Share of records by publication typeReviews: 4.3 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 1.1 percentReviews4.3% (164)Meta-analyses0.1% (2)Randomized controlled trials1.1% (41)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 3,787 PubMed records
TypeRecordsShare
Reviews1644.3%
Meta-analyses20.1%
Randomized controlled trials411.1%

Method: PubMed query "Guanethidine"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate
Espinoza JA, Alvarado W, Venegas B, Domínguez R, Morales-Ledesma L
2018Research article
Design not recorded in structured metadata
11cc by
PMID 30193590 · DOI · PMC6128994
The Influence of an Adrenergic Antagonist Guanethidine (GUA) on the Distribution Pattern and Chemical Coding of Dorsal Root Ganglia (DRG) Neurons Supplying the Porcine Urinary Bladder
Janikiewicz P, Wasilewska B, Mazur U, Franke-Radowiecka A, Majewski M, Bossowska A
2021Research article
Design not recorded in structured metadata
7cc by
PMID 34948196 · DOI · PMC8708101
The Influence of an Adrenergic Antagonist Guanethidine on the Distribution Pattern and Chemical Coding of Caudal Mesenteric Ganglion Perikarya and Their Axons Supplying the Porcine Bladder
Bossowska A, Lepiarczyk E, Janikiewicz P, Wasilewska B, Mazur U, Markiewicz W, et al.
2021Research article
Design not recorded in structured metadata
1cc by
PMID 34063103 · DOI · PMC8124201

Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate [1]

Research article Espinoza JA, Alvarado W, Venegas B, Domínguez R, Morales-Ledesma L · · 2018 · cited 11 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe injection of estradiol valerate in female rats induces polycystic ovary syndrome, which is characterized by polycystic ovaries, anovulation, and hyperandrogenism.
Closing excerpt
ConclusionThe results of the present study suggest that the noradrenergic fibers play a stimulant role in the establishment of polycystic ovary syndrome.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (320 words)

BackgroundThe injection of estradiol valerate in female rats induces polycystic ovary syndrome, which is characterized by polycystic ovaries, anovulation, and hyperandrogenism. These characteristics have been associated with an increase in the ovarian concentration of norepinephrine, which occurs before establishing the polycystic ovary syndrome. The bilateral section of the superior ovarian nerve restores ovarian functions in animals with polycystic ovary syndrome. The superior ovarian nerve provides norepinephrine and vasoactive intestinal peptide to the ovary. An increase in the activity of both neurotransmitters has been associated with the development of polycystic ovary syndrome. The purpose of the present study was analyzed the participation of the noradrenergic nervous system in the development of polycystic ovary syndrome using guanethidine as a pharmacological tool that destroys peripheral noradrenergic nerve fibers.MethodsFourteen-day old female rats of the CIIZ-V strain were injected with estradiol valerate or vehicle solution. Rats were randomly allotted to one of three guanethidine treatment groups for denervation: 1) guanethidine treatment at age 7 to 27-days, 2) guanethidine treatment at age 14 to 34- days, and 3) guanethidine treatment at age 70 to 90- days. All animals were sacrificed when presenting vaginal oestrus at age 90 to 94-days. The parameters analyzed were the number of ova shed by ovulating animals, the ovulation rate (i.e., the numbers of ovulating animals/the numbers of used animals), the serum concentration of progesterone, testosterone, oestradiol and the immunoreactivity for tyrosine hydroxylase enzyme. All data were analyzed statistically. A p-value of less than 0.05 was considered significant.ResultsOur results show that the elimination of noradrenergic fibers before the establishment of polycystic ovary syndrome prevents two characteristics of the syndrome, blocking of ovulation and hyperandrogenism. We also found that in animals that have already developed polycystic ovary syndrome, sympathetic denervation restores ovulatory capacity, but it was not as efficient in reducing hyperandrogenism.ConclusionThe results of the present study suggest that the noradrenergic fibers play a stimulant role in the establishment of polycystic ovary syndrome.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30193590 · DOI · PMC6128994

The Influence of an Adrenergic Antagonist Guanethidine (GUA) on the Distribution Pattern and Chemical Coding of Dorsal Root Ganglia (DRG) Neurons Supplying the Porcine Urinary Bladder [2]

Research article Janikiewicz P, Wasilewska B, Mazur U, Franke-Radowiecka A, Majewski M, Bossowska A · · 2021 · cited 7 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Although guanethidine (GUA) was used in the past as a drug to suppress hyperactivity of the sympathetic nerve fibers, there are no available data concerning the possible action of this substance on the sensory component of the peripheral nervous system supplying the urinary bladder.
Closing excerpt
The present study provides evidence that GUA significantly modifies the sensory innervation of the porcine urinary bladder wall and thus may be considered a potential tool for studying the plasticity of this subdivision of the bladder innervation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (249 words)

Although guanethidine (GUA) was used in the past as a drug to suppress hyperactivity of the sympathetic nerve fibers, there are no available data concerning the possible action of this substance on the sensory component of the peripheral nervous system supplying the urinary bladder. Thus, the present study was aimed at disclosing the influence of intravesically instilled GUA on the distribution, relative frequency, and chemical coding of dorsal root ganglion neurons associated with the porcine urinary bladder. The investigated sensory neurons were visualized with a retrograde tracing method using Fast Blue (FB), while their chemical profile was disclosed with single-labeling immunohistochemistry using antibodies against substance P (SP), calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase activating polypeptide (PACAP), galanin (GAL), neuronal nitric oxide synthase (nNOS), somatostatin (SOM), and calbindin (CB). After GUA treatment, a slight decrease in the number of FB+ neurons containing SP was observed when compared with untreated animals (34.6 ± 6.5% vs. 45.6 ± 1.3%), while the number of retrogradely traced cells immunolabeled for GAL, nNOS, and CB distinctly increased (12.3 ± 1.0% vs. 7.4 ± 0.6%, 11.9 ± 0.6% vs. 5.4 ± 0.5% and 8.6 ± 0.5% vs. 2.7 ± 0.4%, respectively). However, administration of GUA did not change the number of FB+ neurons containing CGRP, PACAP, or SOM. The present study provides evidence that GUA significantly modifies the sensory innervation of the porcine urinary bladder wall and thus may be considered a potential tool for studying the plasticity of this subdivision of the bladder innervation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34948196 · DOI · PMC8708101

The Influence of an Adrenergic Antagonist Guanethidine on the Distribution Pattern and Chemical Coding of Caudal Mesenteric Ganglion Perikarya and Their Axons Supplying the Porcine Bladder [3]

Research article Bossowska A, Lepiarczyk E, Janikiewicz P, Wasilewska B, Mazur U, Markiewicz W, et al. · · 2021 · cited 1 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
This study was aimed at disclosing the influence of intravesically instilled guanethidine (GUA) on the distribution, relative frequency and chemical coding of both the urinary bladder intramural sympathetic nerve fibers and their parent cell bodies in the caudal mesenteric ganglion (CaMG) in juvenile female pigs.
Closing excerpt
The present study provides evidence that GUA significantly modifies the sympathetic innervation of the porcine urinary bladder wall, and thus may be considered a potential tool for studying the plasticity of this subdivision of the bladder innervation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (224 words)

This study was aimed at disclosing the influence of intravesically instilled guanethidine (GUA) on the distribution, relative frequency and chemical coding of both the urinary bladder intramural sympathetic nerve fibers and their parent cell bodies in the caudal mesenteric ganglion (CaMG) in juvenile female pigs. GUA instillation led to a profound decrease in the number of perivascular nerve terminals. Furthermore, the chemical profile of the perivascular innervation within the treated bladder also distinctly changed, as most of axons became somatostatin-immunoreactive (SOM-IR), while in the control animals they were found to be neuropeptide Y (NPY)-positive. Intravesical treatment with GUA led not only to a significant decrease in the number of bladder-projecting tyrosine hydroxylase (TH) CaMG somata (94.3 ± 1.8% vs. 73.3 ± 1.4%; control vs. GUA-treated pigs), but simultaneously resulted in the rearrangement of their co-transmitters repertoire, causing a distinct decrease in the number of TH+/NPY+ (89.6 ± 0.7% vs. 27.8 ± 0.9%) cell bodies and an increase in the number of SOM-(3.6 ± 0.4% vs. 68.7 ± 1.9%), calbindin-(CB; 2.06 ± 0.2% vs. 9.1 ± 1.2%) or galanin-containing (GAL; 1.6 ± 0.3% vs. 28.2 ± 1.3%) somata. The present study provides evidence that GUA significantly modifies the sympathetic innervation of the porcine urinary bladder wall, and thus may be considered a potential tool for studying the plasticity of this subdivision of the bladder innervation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34063103 · DOI · PMC8124201

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Adynamic ileus, its pathogenesis and treatment [4]
    Furness JB, Costa M · Med Biol · 1974 · cited 71 times (Europe PMC)
  • Research article THE CONTROL OF VENTRICULAR FUNCTION IN MAN [5]
    BRAUNWALD E · Br Heart J · 1965 · cited 36 times (Europe PMC)
  • Research article STUDIES ON THE FUNCTION OF THE ADRENERGIC NERVE ENDINGS IN THE HEART [6]
    BRAUNWALD E, CHIDSEY CA, HARRISON DC, GAFFNEY TE, KAHLER RL · Circulation · 1963 · cited 30 times (Europe PMC)
  • Research article RECENT VIEWS ON MECHANISMS FOR LOWERING SYMPATHETIC TONE [7]
    BRODIE BB · Circulation · 1963 · cited 11 times (Europe PMC)
  • Research article Guanethidine for reflex sympathetic dystrophy [8]
    Yasuda JM, Schroeder DJ · Ann Pharmacother · 1994 · cited 7 times (Europe PMC)
  • Research article Treatment of algodystrophy using intravenous guanethidine regional block [9]
    Jacquemoud G, Chamay A · Ann Chir Main · 1982 · cited 7 times (Europe PMC)

References

  1. Espinoza JA, Alvarado W, Venegas B, Domínguez R, Morales-Ledesma L. Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate. . 2018. PMID 30193590 · DOI · PMC6128994
  2. Janikiewicz P, Wasilewska B, Mazur U, Franke-Radowiecka A, Majewski M, Bossowska A. The Influence of an Adrenergic Antagonist Guanethidine (GUA) on the Distribution Pattern and Chemical Coding of Dorsal Root Ganglia (DRG) Neurons Supplying the Porcine Urinary Bladder. . 2021. PMID 34948196 · DOI · PMC8708101
  3. Bossowska A, Lepiarczyk E, Janikiewicz P, Wasilewska B, Mazur U, Markiewicz W, et al.. The Influence of an Adrenergic Antagonist Guanethidine on the Distribution Pattern and Chemical Coding of Caudal Mesenteric Ganglion Perikarya and Their Axons Supplying the Porcine Bladder. . 2021. PMID 34063103 · DOI · PMC8124201
  4. Furness JB, Costa M. Adynamic ileus, its pathogenesis and treatment. Med Biol. 1974. PMID 4365867
  5. BRAUNWALD E. THE CONTROL OF VENTRICULAR FUNCTION IN MAN. Br Heart J. 1965. PMID 14242160 · DOI · PMC490129
  6. BRAUNWALD E, CHIDSEY CA, HARRISON DC, GAFFNEY TE, KAHLER RL. STUDIES ON THE FUNCTION OF THE ADRENERGIC NERVE ENDINGS IN THE HEART. Circulation. 1963. PMID 14079202 · DOI
  7. BRODIE BB. RECENT VIEWS ON MECHANISMS FOR LOWERING SYMPATHETIC TONE. Circulation. 1963. PMID 14085298 · DOI
  8. Yasuda JM, Schroeder DJ. Guanethidine for reflex sympathetic dystrophy. Ann Pharmacother. 1994. PMID 8193423
  9. Jacquemoud G, Chamay A. Treatment of algodystrophy using intravenous guanethidine regional block. Ann Chir Main. 1982. PMID 9303043 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • GuanidineDrugs and Chemicals
  • CimetidineDrugs and Chemicals
  • CreatineDrugs and Chemicals
  • MetforminDrugs and Chemicals
  • KanamycinDrugs and Chemicals
  • Linoleic AcidDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

3,787
PubMed records on this heading
0%
published since 2020
164
review articles
41
randomized trials
9
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • GuanidineDrugs and Chemicals
  • CimetidineDrugs and Chemicals
  • CreatineDrugs and Chemicals
  • MetforminDrugs and Chemicals
  • KanamycinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support